KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Current Taxes: 2012-2025

Historic Current Taxes for Jazz Pharmaceuticals (JAZZ) over the last 14 years, with Sep 2025 value amounting to $91.1 million.

  • Jazz Pharmaceuticals' Current Taxes rose 65.79% to $91.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $91.1 million, marking a year-over-year increase of 65.79%. This contributed to the annual value of $18.8 million for FY2024, which is 46.52% down from last year.
  • Jazz Pharmaceuticals' Current Taxes amounted to $91.1 million in Q3 2025, which was up 16.03% from $78.5 million recorded in Q2 2025.
  • In the past 5 years, Jazz Pharmaceuticals' Current Taxes ranged from a high of $91.1 million in Q3 2025 and a low of $3.6 million during Q2 2021.
  • Moreover, its 3-year median value for Current Taxes was $52.1 million (2024), whereas its average is $55.3 million.
  • Its Current Taxes has fluctuated over the past 5 years, first plummeted by 93.49% in 2021, then soared by 1,065.10% in 2023.
  • Quarterly analysis of 5 years shows Jazz Pharmaceuticals' Current Taxes stood at $9.6 million in 2021, then declined by 19.68% to $7.7 million in 2022, then surged by 354.50% to $35.1 million in 2023, then tumbled by 46.52% to $18.8 million in 2024, then soared by 65.79% to $91.1 million in 2025.
  • Its last three reported values are $91.1 million in Q3 2025, $78.5 million for Q2 2025, and $31.8 million during Q1 2025.